Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Leukemia

Free Subscription Articles published in Cancer Retrieve available abstracts of 132 articles: HTML format Text format

Single Articles

October 2019
1. ZHANG C, Lam SSY, Leung GMK, Tsui SP, et al
   Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.
   Cancer. 2019 Oct 3. doi: 10.1002/cncr.32534.
   PubMed     Text format     Abstract available
   
   
   September 2019
2. JIM HSL, Hyland KA, Nelson AM, Pinilla-Ibarz J, et al
   Internet-assisted cognitive behavioral intervention for targeted therapy-related fatigue in chronic myeloid leukemia: Results from a pilot randomized trial.
   Cancer. 2019 Sep 25. doi: 10.1002/cncr.32521.
   PubMed     Text format     Abstract available
   
   
   
3. NAQVI K, Jabbour E, Skinner J, Anderson K, et al
   Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.
   Cancer. 2019 Sep 25. doi: 10.1002/cncr.32504.
   PubMed     Text format     Abstract available
   
   
   
4. BLOOMHARDT HM, Sint K, Ross WL, Rotatori J, et al
   Severity of reduced bone mineral density and risk of fractures in long-term survivors of childhood leukemia and lymphoma undergoing guideline-recommended surveillance for bone health.
   Cancer. 2019 Sep 19. doi: 10.1002/cncr.32512.
   PubMed     Text format     Abstract available
   
   
   
5. ZEIDAN AM, Podoltsev NA, Wang X, Bewersdorf JP, et al
   Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population-level analysis.
   Cancer. 2019 Sep 4. doi: 10.1002/cncr.32439.
   PubMed     Text format     Abstract available
   
   
   August 2019
6. JABBOUR EJ, Gokbuget N, Kantarjian HM, Thomas X, et al
   Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study.
   Cancer. 2019 Aug 21. doi: 10.1002/cncr.32335.
   PubMed     Text format     Abstract available
   
   
   
7. WU J, Chen Y, Hageman L, Francisco L, et al
   Late mortality after bone marrow transplant for chronic myelogenous leukemia in the context of prior tyrosine kinase inhibitor exposure: A Blood or Marrow Transplant Survivor Study (BMTSS) report.
   Cancer. 2019 Aug 14. doi: 10.1002/cncr.32443.
   PubMed     Text format     Abstract available
   
   
   
8. MONTSERRAT E, Gale RP
   Predicting the outcome of patients with chronic lymphocytic leukemia: Progress and uncertainty.
   Cancer. 2019 Aug 5. doi: 10.1002/cncr.32353.
   PubMed     Text format     Abstract available
   
   
   July 2019
9. BOULET-CRAIG A, Robaey P, Barlaam F, Laniel J, et al
   Visual short-term memory activation patterns in adult survivors of childhood acute lymphoblastic leukemia.
   Cancer. 2019 Jul 16. doi: 10.1002/cncr.32374.
   PubMed     Text format     Abstract available
   
   
   
10. SASAKI K, Kantarjian HM, Kadia T, Patel K, et al
    Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.
    Cancer. 2019 Jul 16. doi: 10.1002/cncr.32387.
    PubMed     Text format     Abstract available
    
    
    
11. SLAVIN SD, Fenech A, Jankowski AL, Abel GA, et al
    Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission.
    Cancer. 2019 Jul 12. doi: 10.1002/cncr.32397.
    PubMed     Text format     Abstract available
    
    
    
12. PERCIVAL MM, Estey EH
    Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia.
    Cancer. 2019 Jul 10. doi: 10.1002/cncr.32354.
    PubMed     Text format     Abstract available
    
    
    June 2019
13. SHOUVAL R, Labopin M, Gorin NC, Bomze D, et al
    Individualized prediction of leukemia-free survival after autologous stem cell transplantation in acute myeloid leukemia.
    Cancer. 2019 Jun 21. doi: 10.1002/cncr.32344.
    PubMed     Text format     Abstract available
    
    
    May 2019
14. CHAMOUN K, Kantarjian HM, Wang X, Naqvi K, et al
    Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia.
    Cancer. 2019 May 31. doi: 10.1002/cncr.32196.
    PubMed     Text format     Abstract available
    
    
    
15. GILL H, Kumana CR, Yim R, Hwang YY, et al
    Oral arsenic trioxide incorporation into frontline treatment with all-trans retinoic acid and chemotherapy in newly diagnosed acute promyelocytic leukemia: A 5-year prospective study.
    Cancer. 2019 May 15. doi: 10.1002/cncr.32180.
    PubMed     Text format     Abstract available
    
    
    April 2019
16. EL EIT R, Itani AR, Nassar F, Rasbieh N, et al
    Antitumor efficacy of arsenic/interferon in preclinical models of chronic myeloid leukemia resistant to tyrosine kinase inhibitors.
    Cancer. 2019 Apr 29. doi: 10.1002/cncr.32130.
    PubMed     Text format     Abstract available
    
    
    
17. RIBERA JM, Garcia O, Moreno MJ, Barba P, et al
    Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group.
    Cancer. 2019 Apr 23. doi: 10.1002/cncr.32156.
    PubMed     Text format     Abstract available
    
    
    
18. JABBOUR EJ, Sasaki K, Ravandi F, Short NJ, et al
    Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblas
    Cancer. 2019 Apr 15. doi: 10.1002/cncr.32139.
    PubMed     Text format     Abstract available
    
    
    
19. KENZIK KM, Bhatia R, Williams GR, Bhatia S, et al
    Medicare and patient spending among beneficiaries diagnosed with chronic myelogenous leukemia.
    Cancer. 2019 Apr 11. doi: 10.1002/cncr.32137.
    PubMed     Text format     Abstract available
    
    
    March 2019
20. KANTARJIAN HM, DeAngelo DJ, Stelljes M, Liedtke M, et al
    Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.
    Cancer. 2019 Mar 28. doi: 10.1002/cncr.32116.
    PubMed     Text format     Abstract available
    
    
    
21. VANDSEMB EN, Kim TK, Zeidan AM
    Will deeper characterization of the landscape of immune checkpoint molecules in acute myeloid leukemia bone marrow lead to improved therapeutic targeting?
    Cancer. 2019 Mar 12. doi: 10.1002/cncr.32042.
    PubMed     Text format    
    
    
    February 2019
22. BENTON CB, Boddu PC, DiNardo CD, Bose P, et al
    Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.
    Cancer. 2019 Feb 27. doi: 10.1002/cncr.31986.
    PubMed     Text format     Abstract available
    
    
    
23. GHAZAWI FM, Le M, Cyr J, Netchiporouk E, et al
    Analysis of acute myeloid leukemia incidence and geographic distribution in Canada from 1992 to 2010 reveals disease clusters in Sarnia and other industrial US border cities in Ontario.
    Cancer. 2019 Feb 27. doi: 10.1002/cncr.32034.
    PubMed     Text format     Abstract available
    
    
    
24. SAMET JM, Cockburn M
    What can be learned from mapping the occurrence of acute myeloid leukemia?
    Cancer. 2019 Feb 27. doi: 10.1002/cncr.32031.
    PubMed     Text format    
    
    
    
25. SHARMA S, Rai KR
    Chronic lymphocytic leukemia (CLL) treatment: So many choices, such great options.
    Cancer. 2019 Feb 26. doi: 10.1002/cncr.31931.
    PubMed     Text format     Abstract available
    
    
    
26. PRINTZ C
    Neurotoxicity more likely in Hispanic children treated for acute lymphoblastic leukemia.
    Cancer. 2019;125:494-495.
    PubMed     Text format    
    
    
    
27. D'ADDA M, Farina M, Schieppati F, Borlenghi E, et al
    The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
    Cancer. 2019 Feb 1. doi: 10.1002/cncr.31977.
    PubMed     Text format     Abstract available
    
    
    January 2019
28. KRULL KR, Li C, Phillips NS, Cheung YT, et al
    Growth hormone deficiency and neurocognitive function in adult survivors of childhood acute lymphoblastic leukemia.
    Cancer. 2019 Jan 28. doi: 10.1002/cncr.31975.
    PubMed     Text format     Abstract available
    
    
    
29. KANTARJIAN HM, Jabbour EJ, Garcia-Manero G, Kadia TM, et al
    Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia.
    Cancer. 2019 Jan 22. doi: 10.1002/cncr.31923.
    PubMed     Text format     Abstract available
    
    
    
30. SANTORO N, Labopin M, Ciceri F, Van Lint MT, et al
    Impact of conditioning intensity on outcomes of haploidentical stem cell transplantation for patients with acute myeloid leukemia over 45 years of age.
    Cancer. 2019 Jan 8. doi: 10.1002/cncr.31941.
    PubMed     Text format     Abstract available
    
    
    December 2018
31. CHIARETTI S, Messina M, Foa R
    BCR/ABL1-like acute lymphoblastic leukemia: How to diagnose and treat?
    Cancer. 2018 Dec 18. doi: 10.1002/cncr.31848.
    PubMed     Text format     Abstract available
    
    
    
32. CALIP GS, Moran KM, Sweiss KI, Patel PR, et al
    Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma.
    Cancer. 2018 Dec 12. doi: 10.1002/cncr.31914.
    PubMed     Text format     Abstract available
    
    
    
33. BODDU PC, Kadia TM, Garcia-Manero G, Cortes J, et al
    Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes.
    Cancer. 2018 Dec 6. doi: 10.1002/cncr.31885.
    PubMed     Text format     Abstract available
    
    
    
34. YOON JH, Min GJ, Park SS, Jeon YW, et al
    Minimal residual disease-based long-term efficacy of reduced-intensity conditioning versus myeloablative conditioning for adult Philadelphia-positive acute lymphoblastic leukemia.
    Cancer. 2018 Dec 6. doi: 10.1002/cncr.31874.
    PubMed     Text format     Abstract available
    
    
    
35. KANAGAL-SHAMANNA R, Jain P, Patel KP, Routbort M, et al
    Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
    Cancer. 2018 Dec 3. doi: 10.1002/cncr.31831.
    PubMed     Text format     Abstract available
    
    
    November 2018
36. WILLIAMS P, Basu S, Garcia-Manero G, Hourigan CS, et al
    The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia.
    Cancer. 2018 Nov 30. doi: 10.1002/cncr.31896.
    PubMed     Text format     Abstract available
    
    
    
37. SIMONETTI G, Padella A, do Valle IF, Fontana MC, et al
    Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery.
    Cancer. 2018 Nov 27. doi: 10.1002/cncr.31837.
    PubMed     Text format     Abstract available
    
    
    
38. KLIL-DRORI AJ, Yin H, Azoulay L, Del Corpo A, et al
    Molecular monitoring of therapeutic milestones and clinical outcomes in patients with chronic myeloid leukemia.
    Cancer. 2018 Nov 13. doi: 10.1002/cncr.31835.
    PubMed     Text format     Abstract available
    
    
    
39. BRUNNER AM, Neuberg DS, Wander SA, Sadrzadeh H, et al
    Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia.
    Cancer. 2018 Nov 13. doi: 10.1002/cncr.31729.
    PubMed     Text format     Abstract available
    
    
    October 2018
40. BROWNE EK, Zhou Y, Chemaitilly W, Panetta JC, et al
    Changes in body mass index, height, and weight in children during and after therapy for acute lymphoblastic leukemia.
    Cancer. 2018 Oct 25. doi: 10.1002/cncr.31736.
    PubMed     Text format     Abstract available
    
    
    
41. BAILEY C, Richardson LC, Allemani C, Bonaventure A, et al
    Adult leukemia survival trends in the United States by subtype: A population-based registry study of 370,994 patients diagnosed during 1995-2009.
    Cancer. 2018 Oct 21. doi: 10.1002/cncr.31674.
    PubMed     Text format     Abstract available
    
    
    
42. SEYMOUR EK, Ruterbusch JJ, Beebe-Dimmer JL, Schiffer CA, et al
    Real-world testing and treatment patterns in chronic lymphocytic leukemia: A SEER patterns of care analysis.
    Cancer. 2018 Oct 21. doi: 10.1002/cncr.31738.
    PubMed     Text format     Abstract available
    
    
    
43. MINA R, Joseph NS, Kaufman JL, Gupta VA, et al
    Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
    Cancer. 2018 Oct 17. doi: 10.1002/cncr.31718.
    PubMed     Text format     Abstract available
    
    
    
44. HIDALGO-LOMICRONPEZ JE, Kanagal-Shamanna R, Quesada AE, Gong Z, et al
    Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: Assessment of potential value.
    Cancer. 2018 Oct 15. doi: 10.1002/cncr.31663.
    PubMed     Text format     Abstract available
    
    
    
45. JABBOUR E, Sasaki K, Ravandi F, Huang X, et al
    Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
    Cancer. 2018 Oct 11. doi: 10.1002/cncr.31720.
    PubMed     Text format     Abstract available
    
    
    
46. PUI CH
    To delay or not to delay, that is the question for patients with acute lymphoblastic leukemia who do not receive prophylactic cranial irradiation.
    Cancer. 2018 Oct 10. doi: 10.1002/cncr.31756.
    PubMed     Text format    
    
    
    
47. YEH TC, Liang DC, Hou JY, Jaing TH, et al
    Treatment of childhood acute lymphoblastic leukemia with delayed first intrathecal therapy and omission of prophylactic cranial irradiation: Results of the TPOG-ALL-2002 study.
    Cancer. 2018 Oct 10. doi: 10.1002/cncr.31758.
    PubMed     Text format     Abstract available
    
    
    
48. TRUONG TH, Pole JD, Barber R, Dix D, et al
    Enrollment on clinical trials does not improve survival for children with acute myeloid leukemia: A population-based study.
    Cancer. 2018 Oct 6. doi: 10.1002/cncr.31728.
    PubMed     Text format     Abstract available
    
    
    
49. NAQVI K, Kantarjian HM
    Reply to Starting with a lower daily dose of dasatinib in patients with chronic myeloid leukemia in chronic phase: Less is more, or is it?
    Cancer. 2018 Oct 1. doi: 10.1002/cncr.31683.
    PubMed     Text format    
    
    
    
50. ESKAZAN AE
    Starting with a lower daily dose of dasatinib in patients with chronic myeloid leukemia in chronic phase: Less is more, or is it?
    Cancer. 2018 Oct 1. doi: 10.1002/cncr.31682.
    PubMed     Text format    
    
    
    June 2018
51. ZHANG Y, Wang F, Chen X, Zhang Y, et al
    CSF3R mutations are frequently associated with abnormalities of RUNX1, CBFB, CEBPA, and NPM1 genes in acute myeloid leukemia.
    Cancer. 2018 Jun 22. doi: 10.1002/cncr.31586.
    PubMed     Text format     Abstract available
    
    
    
52. PRINTZ C
    First person: Hagop Kantarjian, MD: MD Anderson physician reflects on decades of leading research into new leukemia drugs.
    Cancer. 2018;124:2469.
    PubMed     Text format    
    
    
    May 2018
53. ARELLANO M, Carlisle JW
    How I treat older patients with acute myeloid leukemia.
    Cancer. 2018 May 29. doi: 10.1002/cncr.31347.
    PubMed     Text format    
    
    
    
54. GORDON MJ, Churnetski M, Alqahtani H, Rivera X, et al
    Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib.
    Cancer. 2018 May 24. doi: 10.1002/cncr.31554.
    PubMed     Text format     Abstract available
    
    
    
55. 
    Erratum: Fathi AT, Blonquist TM, Hernandez D, et al. Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation. Cancer. 2018;124:306-314.
    Cancer. 2018;124:2258.
    PubMed     Text format    
    
    
    
56. PRINTZ C
    First person: John Byrd, MD: This Ohio State University researcher has been developing transformative treatments for patients with chronic lymphocytic leukemia, and now is setting his sights on individuals with acute myeloid leukemia.
    Cancer. 2018;124:2069.
    PubMed     Text format    
    
    
    
57. ANDERSEN BL, Goyal NG, Weiss DM, Westbrook TD, et al
    Cells, cytokines, chemokines, and cancer stress: A biobehavioral study of patients with chronic lymphocytic leukemia.
    Cancer. 2018 May 14. doi: 10.1002/cncr.31538.
    PubMed     Text format     Abstract available
    
    
    
58. REA D, Ame S, Berger M, Cayuela JM, et al
    Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.
    Cancer. 2018 May 3. doi: 10.1002/cncr.31411.
    PubMed     Text format     Abstract available
    
    
    
59. NAQVI K, Jabbour E, Skinner J, Yilmaz M, et al
    Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.
    Cancer. 2018 May 3. doi: 10.1002/cncr.31357.
    PubMed     Text format     Abstract available
    
    
    April 2018
60. ARTS LPJ, Oerlemans S, Tick L, Koster A, et al
    More frequent use of health care services among distressed compared with nondistressed survivors of lymphoma and chronic lymphocytic leukemia: Results from the population-based PROFILES registry.
    Cancer. 2018 Apr 26. doi: 10.1002/cncr.31410.
    PubMed     Text format     Abstract available
    
    
    
61. ERCALISKAN A, Eskazan AE
    The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia.
    Cancer. 2018 Apr 25. doi: 10.1002/cncr.31408.
    PubMed     Text format     Abstract available
    
    
    
62. ASSI R, Kantarjian HM, Kadia TM, Pemmaraju N, et al
    Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
    Cancer. 2018 Apr 16. doi: 10.1002/cncr.31398.
    PubMed     Text format     Abstract available
    
    
    
63. KANTARJIAN HM, DiNardo CD, Nogueras-Gonzalez GM, Kadia TM, et al
    Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.
    Cancer. 2018 Apr 12. doi: 10.1002/cncr.31370.
    PubMed     Text format     Abstract available
    
    
    
64. DINARDO CD, Routbort MJ, Bannon SA, Benton CB, et al
    Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels.
    Cancer. 2018 Apr 6. doi: 10.1002/cncr.31331.
    PubMed     Text format     Abstract available
    
    
    March 2018
65. CZERW T, Labopin M, Giebel S, Socie G, et al
    Anti-thymocyte globulin improves survival free from relapse and graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia-negative acute lymphoblastic leukemia: An analysis by the Acute Leukemi
    Cancer. 2018 Mar 30. doi: 10.1002/cncr.31354.
    PubMed     Text format     Abstract available
    
    
    
66. GILL H, Yim R, Lee HKK, Mak V, et al
    Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: A 15-year prospective study.
    Cancer. 2018 Mar 26. doi: 10.1002/cncr.31327.
    PubMed     Text format     Abstract available
    
    
    
67. XUAN L, Wang Y, Huang F, Jiang E, et al
    Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation.
    Cancer. 2018 Mar 6. doi: 10.1002/cncr.31295.
    PubMed     Text format     Abstract available
    
    
    
68. KANTARJIAN HM, Su Y, Jabbour EJ, Bhattacharyya H, et al
    Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia.
    Cancer. 2018 Mar 6. doi: 10.1002/cncr.31317.
    PubMed     Text format     Abstract available
    
    
    
69. EFFICACE F, Castagnetti F, Martino B, Breccia M, et al
    Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.
    Cancer. 2018 Mar 2. doi: 10.1002/cncr.31323.
    PubMed     Text format     Abstract available
    
    
    February 2018
70. CIUREA SO, Labopin M, Socie G, Volin L, et al
    Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center.
    Cancer. 2018 Feb 22. doi: 10.1002/cncr.31311.
    PubMed     Text format     Abstract available
    
    
    
71. SESTILI S, Labopin M, Ruggeri A, Velardi A, et al
    T-cell-depleted haploidentical stem cell transplantation results improve with time in adults with acute leukemia: A study from the Acute Leukemia Working Party of the European Society of Blood and Marrow Transplantation (EBMT).
    Cancer. 2018 Feb 22. doi: 10.1002/cncr.31310.
    PubMed     Text format     Abstract available
    
    
    
72. HO G, Wun T, Muffly L, Li Q, et al
    Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute-designated cancer centers in California.
    Cancer. 2018 Feb 16. doi: 10.1002/cncr.31296.
    PubMed     Text format     Abstract available
    
    
    
73. PRINTZ C
    First person: Ali Bazarbachi, MD, PhD: The professor at the American University of Beirut has advanced the treatment of leukemia and cancer research in the Middle East and worldwide.
    Cancer. 2018;124:661-662.
    PubMed     Text format    
    
    
    January 2018
74. JABBOUR EJ, DeAngelo DJ, Stelljes M, Stock W, et al
    Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE.
    Cancer. 2018 Jan 30. doi: 10.1002/cncr.31249.
    PubMed     Text format     Abstract available
    
    
    
75. TALPAZ M, Saglio G, Atallah E, Rousselot P, et al
    Dasatinib dose management for the treatment of chronic myeloid leukemia.
    Cancer. 2018 Jan 25. doi: 10.1002/cncr.31232.
    PubMed     Text format     Abstract available
    
    
    
76. RUGGERI A, Labopin M, Bacigalupo A, Gulbas Z, et al
    Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide.
    Cancer. 2018 Jan 23. doi: 10.1002/cncr.31228.
    PubMed     Text format     Abstract available
    
    
    December 2017
77. BALTZELL KA, Shen HM, Krishnamurty S, Sison JD, et al
    Bovine leukemia virus linked to breast cancer but not coinfection with human papillomavirus: Case-control study of women in Texas.
    Cancer. 2017 Dec 20. doi: 10.1002/cncr.31169.
    PubMed     Text format     Abstract available
    
    
    
78. SASAKI K, Kantarjian H, O'Brien S, Ravandi F, et al
    Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase.
    Cancer. 2017 Dec 20. doi: 10.1002/cncr.31187.
    PubMed     Text format     Abstract available
    
    
    
79. SALZER WL, Burke MJ, Devidas M, Chen S, et al
    Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131.
    Cancer. 2017 Dec 19. doi: 10.1002/cncr.31099.
    PubMed     Text format     Abstract available
    
    
    
80. INABA H, Cao X, Han AQ, Panetta JC, et al
    Bone mineral density in children with acute lymphoblastic leukemia.
    Cancer. 2017 Dec 19. doi: 10.1002/cncr.31184.
    PubMed     Text format     Abstract available
    
    
    
81. TAI EW, Ward KC, Bonaventure A, Siegel DA, et al
    Survival among children diagnosed with acute lymphoblastic leukemia in the United States, by race and age, 2001 to 2009: Findings from the CONCORD-2 study.
    Cancer. 2017;123 Suppl 24:5178-5189.
    PubMed     Text format     Abstract available
    
    
    
82. ABAZA YM, Kadia TM, Jabbour EJ, Konopleva MY, et al
    Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies.
    Cancer. 2017;123:4851-4859.
    PubMed     Text format     Abstract available
    
    
    
83. ROSENSTOCK AS, Niu J, Giordano SH, Zhao H, et al
    Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients.
    Cancer. 2017 Dec 13. doi: 10.1002/cncr.31144.
    PubMed     Text format     Abstract available
    
    
    
84. MARRIOTT CJC, Beaumont LF, Farncombe TH, Cranston AN, et al
    Body composition in long-term survivors of acute lymphoblastic leukemia diagnosed in childhood and adolescence: A focus on sarcopenic obesity.
    Cancer. 2017 Dec 12. doi: 10.1002/cncr.31191.
    PubMed     Text format     Abstract available
    
    
    
85. ROBOZ GJ, Kantarjian HM, Yee KWL, Kropf PL, et al
    Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.
    Cancer. 2017 Dec 6. doi: 10.1002/cncr.31138.
    PubMed     Text format     Abstract available
    
    
    
86. SCHIFFER CA
    "Epigenetic" modification as therapy for acute myeloid leukemia.
    Cancer. 2017 Dec 6. doi: 10.1002/cncr.31137.
    PubMed     Text format    
    
    
    
87. HOWELL CR, Wilson CL, Ehrhardt MJ, Partin RE, et al
    Clinical impact of sedentary behaviors in adult survivors of acute lymphoblastic leukemia: A report from the St. Jude Lifetime Cohort study.
    Cancer. 2017 Dec 4. doi: 10.1002/cncr.31162.
    PubMed     Text format     Abstract available
    
    
    
88. NEUKIRCHEN J, Lauseker M, Hildebrandt B, Nolting AC, et al
    Cytogenetic clonal evolution in myelodysplastic syndromes is associated with inferior prognosis.
    Cancer. 2017;123:4608-4616.
    PubMed     Text format     Abstract available
    
    
    November 2017
89. ZHENG DJ, Lu X, Schore RJ, Balsamo L, et al
    Longitudinal analysis of quality of life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children's Oncology Group AALL0932 trial.
    Cancer. 2017 Nov 7. doi: 10.1002/cncr.31085.
    PubMed     Text format     Abstract available
    
    
    
90. GOLDSBY RE, Stratton KL, Raber S, Ablin A, et al
    Long-term sequelae in survivors of childhood leukemia with Down syndrome: A childhood cancer survivor study report.
    Cancer. 2017 Nov 3. doi: 10.1002/cncr.31065.
    PubMed     Text format     Abstract available
    
    
    
91. FRICK MA, Vachani CC, Bach C, Hampshire MK, et al
    Survivorship and the chronic cancer patient: Patterns in treatment-related effects, follow-up care, and use of survivorship care plans.
    Cancer. 2017;123:4268-4276.
    PubMed     Text format     Abstract available
    
    
    October 2017
92. KANTARJIAN HM, Mamolo CM, Gambacorti-Passerini C, Cortes JE, et al
    Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy.
    Cancer. 2017 Oct 26. doi: 10.1002/cncr.31082.
    PubMed     Text format     Abstract available
    
    
    
93. TIRIBELLI M, Michelutti A, Fanin R, Damiani D, et al
    ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia.
    Cancer. 2017 Oct 20. doi: 10.1002/cncr.31037.
    PubMed     Text format    
    
    
    
94. SHORT NJ, Kantarjian H, Jabbour E
    Reply to ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia.
    Cancer. 2017 Oct 20. doi: 10.1002/cncr.31036.
    PubMed     Text format    
    
    
    
95. SHEN C, Zhao B, Liu L, Shih YT, et al
    Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia.
    Cancer. 2017 Oct 4. doi: 10.1002/cncr.31050.
    PubMed     Text format     Abstract available
    
    
    September 2017
96. FATHI AT, Blonquist TM, Hernandez D, Amrein PC, et al
    Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation.
    Cancer. 2017 Sep 28. doi: 10.1002/cncr.31038.
    PubMed     Text format     Abstract available
    
    
    
97. SCHEICH S, Lindner S, Koenig R, Reinheimer C, et al
    Clinical impact of colonization with multidrug-resistant organisms on outcome after allogeneic stem cell transplantation in patients with acute myeloid leukemia.
    Cancer. 2017 Sep 28. doi: 10.1002/cncr.31045.
    PubMed     Text format     Abstract available
    
    
    
98. BUCKLEY SA, Jimenez-Sahagun D, Othus M, Walter RB, et al
    Quality of life from the perspective of the patient with acute myeloid leukemia.
    Cancer. 2017 Sep 7. doi: 10.1002/cncr.30982.
    PubMed     Text format     Abstract available
    
    
    
99. PRINTZ C
    First person: Rudiger Hehlmann: The professor of medicine and founder of the European LeukemiaNet builds on his hard-won legacy of improving the survival rates of patients with leukemia.
    Cancer. 2017;123:3209-3210.
    PubMed     Text format    
    
    
    August 2017
100. MEDHANIE GA, Fedewa SA, Adissu H, DeSantis CE, et al
     Cancer incidence profile in sub-Saharan African-born blacks in the United States: Similarities and differences with US-born non-Hispanic blacks.
     Cancer. 2017;123:3116-3124.
     PubMed     Text format     Abstract available
     
     
     July 2017
101. LEGROS L, Nicolini FE, Etienne G, Rousselot P, et al
     Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.
     Cancer. 2017 Jul 25. doi: 10.1002/cncr.30885.
     PubMed     Text format     Abstract available
     
     
     
102. JAIN P, Kantarjian HM, Ghorab A, Sasaki K, et al
     Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
     Cancer. 2017 Jul 25. doi: 10.1002/cncr.30864.
     PubMed     Text format     Abstract available
     
     
     
103. JABBOUR E, Short NJ, Ravandi F, Huang X, et al
     A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.
     Cancer. 2017 Jul 14. doi: 10.1002/cncr.30883.
     PubMed     Text format     Abstract available
     
     
     
104. ALVAREZ E, Keegan T, Johnston EE, Haile R, et al
     Adolescent and young adult oncology patients: Disparities in access to specialized cancer centers.
     Cancer. 2017;123:2516-2523.
     PubMed     Text format     Abstract available
     
     
     
105. MARINA NM, Liu Q, Donaldson SS, Sklar CA, et al
     Longitudinal follow-up of adult survivors of Ewing sarcoma: A report from the Childhood Cancer Survivor Study.
     Cancer. 2017;123:2551-2560.
     PubMed     Text format     Abstract available
     
     
     June 2017
106. ARIFFIN H, Azanan MS, Abd Ghafar SS, Oh L, et al
     Young adult survivors of childhood acute lymphoblastic leukemia show evidence of chronic inflammation and cellular aging.
     Cancer. 2017 Jun 27. doi: 10.1002/cncr.30857.
     PubMed     Text format     Abstract available
     
     
     
107. ZEIDAN AM, Hu X, Long JB, Wang R, et al
     Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study.
     Cancer. 2017 Jun 16. doi: 10.1002/cncr.30814.
     PubMed     Text format     Abstract available
     
     
     
108. KANAGAL-SHAMANNA R, Jain P, Takahashi K, Short NJ, et al
     TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.
     Cancer. 2017 Jun 13. doi: 10.1002/cncr.30810.
     PubMed     Text format     Abstract available
     
     
     
109. RADICH JP
     Chronic myeloid leukemia: Global impact from a local laboratory.
     Cancer. 2017 Jun 6. doi: 10.1002/cncr.30776.
     PubMed     Text format    
     
     
     May 2017
110. ALEXANDER TB, Wang L, Inaba H, Triplett BM, et al
     Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials.
     Cancer. 2017 May 30. doi: 10.1002/cncr.30791.
     PubMed     Text format     Abstract available
     
     
     
111. LIN CJ, Vader JM, Slade M, DiPersio JF, et al
     Cardiomyopathy in patients after posttransplant cyclophosphamide-based hematopoietic cell transplantation.
     Cancer. 2017;123:1800-1809.
     PubMed     Text format     Abstract available
     
     
     
112. STAHL M, Zeidan AM
     Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.
     Cancer. 2017;123:1703-1713.
     PubMed     Text format     Abstract available
     
     
     
113. LEHMANN V, Tuinman MA, Keim MC, Winning AM, et al
     Psychosexual development and satisfaction in long-term survivors of childhood cancer: Neurotoxic treatment intensity as a risk indicator.
     Cancer. 2017;123:1869-1876.
     PubMed     Text format     Abstract available
     
     
     
114. MILLOT F, Dupraz C, Guilhot J, Suttorp M, et al
     Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: The experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents.
     Cancer. 2017 May 12. doi: 10.1002/cncr.30767.
     PubMed     Text format     Abstract available
     
     
     
115. PERRY AM, Brunner AM, Zou T, McGregor KL, et al
     Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: A population-based study.
     Cancer. 2017 May 2. doi: 10.1002/cncr.30639.
     PubMed     Text format     Abstract available
     
     
     
116. MAURO MJ
     Running the marathon of chronic myeloid leukemia with no shoes (or without the right shoes)!
     Cancer. 2017 May 2. doi: 10.1002/cncr.30638.
     PubMed     Text format    
     
     
     
117. SHIELD PW, Frost F, Finnimore JL, Wright RG, et al
     External quality assurance in nongynecologic cytology: The Australasian experience.
     Cancer. 2017;125:349-361.
     PubMed     Text format     Abstract available
     
     
     April 2017
118. CHEUNG YT, Brinkman TM, Mulrooney DA, Mzayek Y, et al
     Impact of sleep, fatigue, and systemic inflammation on neurocognitive and behavioral outcomes in long-term survivors of childhood acute lymphoblastic leukemia.
     Cancer. 2017 Apr 27. doi: 10.1002/cncr.30742.
     PubMed     Text format     Abstract available
     
     
     
119. SEGAL E, Martens M, Wang HL, Brazauskas R, et al
     Comparing outcomes of matched related donor and matched unrelated donor hematopoietic cell transplants in adults with B-Cell acute lymphoblastic leukemia.
     Cancer. 2017 Apr 27. doi: 10.1002/cncr.30737.
     PubMed     Text format     Abstract available
     
     
     
120. KHOURY HJ, Collins RH Jr, Blum W, Stiff PS, et al
     Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia.
     Cancer. 2017 Apr 14. doi: 10.1002/cncr.30696.
     PubMed     Text format     Abstract available
     
     
     
121. BATTIPAGLIA G, Ruggeri A, Massoud R, El Cheikh J, et al
     Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.
     Cancer. 2017 Apr 7. doi: 10.1002/cncr.30680.
     PubMed     Text format     Abstract available
     
     
     
122. BODDU PC, Kantarjian HM, Ravandi F, Garcia-Manero G, et al
     Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
     Cancer. 2017 Apr 7. doi: 10.1002/cncr.30704.
     PubMed     Text format     Abstract available
     
     
     
123. NICOLINI FE, Basak GW, Kim DW, Olavarria E, et al
     Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.
     Cancer. 2017 Apr 7. doi: 10.1002/cncr.30558.
     PubMed     Text format     Abstract available
     
     
     March 2017
124. NAGLER A, Labopin M, Beelen D, Ciceri F, et al
     Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
     Cancer. 2017 Mar 22. doi: 10.1002/cncr.30646.
     PubMed     Text format     Abstract available
     
     
     
125. RYTTING ME, Jabbour EJ, O'Brien SM, Kantarjian HM, et al
     Acute lymphoblastic leukemia in adolescents and young adults.
     Cancer. 2017 Mar 22. doi: 10.1002/cncr.30624.
     PubMed     Text format     Abstract available
     
     
     
126. YUCEL OK, Saliba RM, Rondon G, Ahmed S, et al
     Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogenic stem cell transplantation using reduced intensity conditioning.
     Cancer. 2017 Mar 21. doi: 10.1002/cncr.30632.
     PubMed     Text format     Abstract available
     
     
     
127. CHANG YJ, Wang Y, Mo XD, Zhang XH, et al
     Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Long-term outcomes of a prospective randomized trial.
     Cancer. 2017 Mar 16. doi: 10.1002/cncr.30540.
     PubMed     Text format     Abstract available
     
     
     February 2017
128. MANYAM BV, Garsa AA, Chin RI, Reddy CA, et al
     A multi-institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck.
     Cancer. 2017 Feb 7. doi: 10.1002/cncr.30601.
     PubMed     Text format     Abstract available
     
     
     
129. 
     First Person: Clara Bloomfield, MD.
     Cancer. 2017;123:369-370.
     PubMed     Text format    
     
     
     January 2017
130. EL-JAWAHRI A, Chen YB, Brazauskas R, He N, et al
     Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation.
     Cancer. 2017 Jan 19. doi: 10.1002/cncr.30546.
     PubMed     Text format     Abstract available
     
     
     
131. PRINTZ C
     Device rapidly measures cell growth and can help determine drug resistance in cancer.
     Cancer. 2017;123:10-11.
     PubMed     Text format    
     
     
     September 2016
132. RAO P, Li Y, Getz KD, Miller TP, et al
     Low rates of pregnancy screening in adolescents before teratogenic exposures in a national sample of children's hospitals.
     Cancer. 2016 Sep 12. doi: 10.1002/cncr.30225.
     PubMed     Text format     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: